首页> 外文OA文献 >A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

【2h】

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

机译：IV阶段随机，开放标签试验研究，以评估从基于蛋白酶抑制剂的方案转换为Bictegravir / Emtrickabine / Tenofovir Alafenamide单片中的单片 - 抑制剂 - Naïve，病毒学抑制的病毒学抑制的HIV-1感染的成人含有耐药性突变（Pibik研究）：用于随机试验的研究方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Collins C. Iwuji; Duncan Churchill; Stephen Bremner; Nicky Perry; Ye To; Debbie Lambert; Chloe Bruce; Laura Waters; Chloe Orkin; Anna Maria Geretti;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na?ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial [J] . Collins C. Iwuji, Duncan Churchill, Stephen Bremner, BMC Infectious Diseases . 2020,第1期

机译：IV阶段随机开放标签试验研究，以评估从基于蛋白酶抑制剂的方案转换为Bictegravir / Emtrickabine / Tenofovir alafenainide单片中的整体酶抑制剂-Na've，病毒学抑制的HIV-1感染的成年人患有耐药性突变（Pibik研究）：随机试验的研究方案
2. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
3. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study [J] . The Lancet infectious diseases . 2016,第1期

机译：在抗逆转录病毒治疗方案中，从病毒学上抑制了HIV-1感染的成年人中，从抗逆转录病毒治疗方案中将富马酸替诺福韦酯改为富马酸替诺福韦阿拉芬酰胺：一项随机，主动控制，多中心，开放标签的3期非劣效性研究
4. Virological Outcome of Tenofovir plus Abacavir-based Regimens in Previously HIV Suppressed Patients (RECOVER STUDY) [C] . S. Moreno, M.J. Perez Elias, J.A. Terron International AIDS Conference . 2004

机译：以前艾滋病病毒抑制患者在替诺福韦加上基于Abacavir的病毒学结果（恢复研究）
5. A phase IV randomised open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial [O] . Collins C. Iwuji, Duncan Churchill, Stephen Bremner, -1

机译：一项IV期随机开放标签的中试研究以评估在无整合酶抑制剂的初治病毒学抑制的具有耐药突变的成人中从基于蛋白酶抑制剂的方案向比昔洛韦/恩曲他滨/替诺福韦Alafenamide单片方案的转换（PIBIK研究）：一项随机试验的研究方案
6. Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：每周48个祖母绿的结果：第3期，随机的非劣升性研究，评估从增强蛋白酶抑制剂（BPI）加上的促蛋白（BPI）和替尼罗韦（FTC）/ Tenofovir Disoproxil umarate（TDF）方案的疗效和安全性对一次每日（QD ），在病毒学抑制的单片机/ Cobicistat / Emtricisabine / enftricitabine / Tenofovir Alafenainide（D / C / F / TAF）的单片植物（str），HIV-1感染的成年人

著录项

引文网络

相似文献

相关主题

期刊订阅